640 related articles for article (PubMed ID: 29718999)
1. Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.
Crooks ET; Grimley SL; Cully M; Osawa K; Dekkers G; Saunders K; Rämisch S; Menis S; Schief WR; Doria-Rose N; Haynes B; Murrell B; Cale EM; Pegu A; Mascola JR; Vidarsson G; Binley JM
PLoS Pathog; 2018 May; 14(5):e1007024. PubMed ID: 29718999
[TBL] [Abstract][Full Text] [Related]
2. Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope.
Pritchard LK; Harvey DJ; Bonomelli C; Crispin M; Doores KJ
J Virol; 2015 Sep; 89(17):8932-44. PubMed ID: 26085151
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
LaBranche CC; McGuire AT; Gray MD; Behrens S; Kwong PDK; Chen X; Zhou T; Sattentau QJ; Peacock J; Eaton A; Greene K; Gao H; Tang H; Perez LG; Chen X; Saunders KO; Kwong PD; Mascola JR; Haynes BF; Stamatatos L; Montefiori DC
PLoS Pathog; 2018 Nov; 14(11):e1007431. PubMed ID: 30395637
[TBL] [Abstract][Full Text] [Related]
4. Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.
Gift SK; Leaman DP; Zhang L; Kim AS; Zwick MB
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978711
[TBL] [Abstract][Full Text] [Related]
5. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
6. Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development.
Andrabi R; Su CY; Liang CH; Shivatare SS; Briney B; Voss JE; Nawazi SK; Wu CY; Wong CH; Burton DR
Immunity; 2017 Sep; 47(3):524-537.e3. PubMed ID: 28916265
[TBL] [Abstract][Full Text] [Related]
7. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.
Fetzer I; Davis-Gardner ME; Gardner MR; Alfant B; Weber JA; Prasad NR; Zhou AS; Farzan M
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541842
[TBL] [Abstract][Full Text] [Related]
8. Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers.
Pritchard LK; Vasiljevic S; Ozorowski G; Seabright GE; Cupo A; Ringe R; Kim HJ; Sanders RW; Doores KJ; Burton DR; Wilson IA; Ward AB; Moore JP; Crispin M
Cell Rep; 2015 Jun; 11(10):1604-13. PubMed ID: 26051934
[TBL] [Abstract][Full Text] [Related]
9. A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies.
Davis-Gardner ME; Alfant B; Weber JA; Gardner MR; Farzan M
mBio; 2020 Jan; 11(1):. PubMed ID: 31937648
[TBL] [Abstract][Full Text] [Related]
10. Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan.
Liang Y; Guttman M; Williams JA; Verkerke H; Alvarado D; Hu SL; Lee KK
J Virol; 2016 Oct; 90(20):9224-36. PubMed ID: 27489265
[TBL] [Abstract][Full Text] [Related]
11. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
[TBL] [Abstract][Full Text] [Related]
13. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
[TBL] [Abstract][Full Text] [Related]
14. Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope.
Schoofs T; Barnes CO; Suh-Toma N; Golijanin J; Schommers P; Gruell H; West AP; Bach F; Lee YE; Nogueira L; Georgiev IS; Bailer RT; Czartoski J; Mascola JR; Seaman MS; McElrath MJ; Doria-Rose NA; Klein F; Nussenzweig MC; Bjorkman PJ
Immunity; 2019 Jun; 50(6):1513-1529.e9. PubMed ID: 31126879
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L
J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423
[TBL] [Abstract][Full Text] [Related]
16. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
[TBL] [Abstract][Full Text] [Related]
17. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.
Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996
[TBL] [Abstract][Full Text] [Related]
18. Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer.
Kong L; Torrents de la Peña A; Deller MC; Garces F; Sliepen K; Hua Y; Stanfield RL; Sanders RW; Wilson IA
Acta Crystallogr D Biol Crystallogr; 2015 Oct; 71(Pt 10):2099-108. PubMed ID: 26457433
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability.
Dubrovskaya V; Tran K; Ozorowski G; Guenaga J; Wilson R; Bale S; Cottrell CA; Turner HL; Seabright G; O'Dell S; Torres JL; Yang L; Feng Y; Leaman DP; Vázquez Bernat N; Liban T; Louder M; McKee K; Bailer RT; Movsesyan A; Doria-Rose NA; Pancera M; Karlsson Hedestam GB; Zwick MB; Crispin M; Mascola JR; Ward AB; Wyatt RT
Immunity; 2019 Nov; 51(5):915-929.e7. PubMed ID: 31732167
[TBL] [Abstract][Full Text] [Related]
20. Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens.
Crooks ET; Almanza F; D'Addabbo A; Duggan E; Zhang J; Wagh K; Mou H; Allen JD; Thomas A; Osawa K; Korber BT; Tsybovsky Y; Cale E; Nolan J; Crispin M; Verkoczy LK; Binley JM
PLoS Pathog; 2021 Oct; 17(10):e1009807. PubMed ID: 34679128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
